Literature DB >> 35127323

A case of Epstein-Barr virus-positive mucocutaneous ulcer of the hypopharynx: a mimicker of hypopharyngeal squamous cell carcinoma.

Sota Masuoka1, Takashi Hiyama1, Hirofumi Kuno1, Yohei Morishita2, Shingo Sakashita3, Tatsushi Kobayashi1.   

Abstract

Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a new disease, described by the World Health Organization in 2017. It has been recognized as a specific type of immunodeficiency-associated lymphoproliferative disorder. Since patients with EBVMCU present with only cutaneous or mucosal ulcers, it is difficult to clinically distinguish them from carcinoma. A 72-year-old man, who took methotrexate (MTX) (12 mg/week) for rheumatoid arthritis, was referred to our hospital because endoscopy revealed an ulcerated mass in the left pyriform sinus, suggesting hypopharyngeal squamous cell carcinoma. Contrast-enhanced computed tomography and magnetic resonance imaging revealed an ill-defined mass in the left pyriform sinus without lymphadenopathy in the head and neck region. A biopsy of the ulcerative lesion in the hypopharynx was performed, and lymphoproliferative disease was suspected, based on the histopathological findings. Two weeks after MTX withdrawal, the lesions in the hypopharynx disappeared. The patient was diagnosed with EBVMCU, based on the clinical and histopathological findings. This is the first case report of EBVMCU of the hypopharynx. EBVMCU should be considered as a differential diagnosis in immunocompromised patients with hypopharyngeal mucosal ulcers without lymph node or organ involvement. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Epstein–Barr virus; Hypopharyngeal cancer; Lymphoproliferative disease; Methotrexate; Ulcer

Year:  2021        PMID: 35127323      PMCID: PMC8787010          DOI: 10.1007/s13691-021-00523-w

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  6 in total

1.  Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders.

Authors:  Kozue Yamada; Yumi Oshiro; Seiichi Okamura; Tomoaki Fujisaki; Seiji Kondo; Yoshifuku Nakayama; Eiichi Suematsu; Kazuo Tamura; Morishige Takeshita
Journal:  Histopathology       Date:  2015-02-05       Impact factor: 5.087

2.  EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.

Authors:  Stefan D Dojcinov; Girish Venkataraman; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 3.  Imaging findings in immunosuppressed patients with Epstein Barr virus-related B cell malignant lymphoma.

Authors:  Alexander Sauter; Christoph Faul; Michael Bitzer; Roland Bares; Sabina Kraus; Michael Fenchel; Marius Horger
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

4.  A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects.

Authors:  Tomoka Ikeda; Yuka Gion; Tadashi Yoshino; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2019

Review 5.  Epstein-Barr Virus-Positive Mucocutaneous Ulcer: A Unique and Curious Disease Entity.

Authors:  Tomoka Ikeda; Yuka Gion; Yoshito Nishimura; Midori Filiz Nishimura; Tadashi Yoshino; Yasuharu Sato
Journal:  Int J Mol Sci       Date:  2021-01-21       Impact factor: 5.923

6.  Clinicopathological analysis of 34 Japanese patients with EBV-positive mucocutaneous ulcer.

Authors:  Tomoka Ikeda; Yuka Gion; Misa Sakamoto; Tomoyasu Tachibana; Asami Nishikori; Midori Filiz Nishimura; Tadashi Yoshino; Yasuharu Sato
Journal:  Mod Pathol       Date:  2020-06-19       Impact factor: 7.842

  6 in total
  1 in total

Review 1.  Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region.

Authors:  Patricia Bott; Ilske Oschlies; Andreas Radeloff; Maureen Loewenthal
Journal:  Curr Oncol       Date:  2022-04-15       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.